F.D.A. Posts Collection of Letters Outlining Concerns About New Drugs

The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs. All eventually passed muster.

More From Author

Want To Be A Biglaw Equity Partner? It’ll Cost Ya!

NYT Connections hints and answers for Sunday, July 13 (game #763)

Leave a Reply

Your email address will not be published. Required fields are marked *